PCMC
CYTK icon

Paragon Capital Management (Colorado)’s Cytokinetics CYTK Stock Holding History

Paragon Capital Management (Colorado)’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,037
Closed -$47K – 253
2021
Q4 		$47K Buy
+1,037
New +$40K 0.01% 346

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Paragon Capital Management (Colorado)'s CYTK Position: Q1 2022 in Review

Paragon Capital Management (Colorado) sold out of Cytokinetics (CYTK) in Q1 2022, closing a stake of 1,037 shares — an estimated $47K sold.

Paragon Capital Management (Colorado) first reported a position in CYTK in Q4 2021 and held it in 1 quarter. The position peaked at $47K in Q4 2021. 240 funds tracked by Wall St. Rank hold CYTK as of Q1 2022.

  • Paragon Capital Management (Colorado) reported no remaining Cytokinetics position as of Q1 2022 after selling out during the quarter.
  • Paragon Capital Management (Colorado) sold 1,037 Cytokinetics shares in Q1 2022, an estimated $47K.
  • Paragon Capital Management (Colorado) first reported a position in Cytokinetics in Q4 2021 and held it in 1 quarter.
  • Paragon Capital Management (Colorado)'s Cytokinetics position peaked at $47K in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2022.

Based on Paragon Capital Management (Colorado)'s 13F filing for Q1 2022, filed 19 Apr 2022.